I’ve spent the last two months cross-referencing intake forms, pricing disclosures, and pharmacy policies from every major compounded GLP-1 provider in the U.S. This isn’t a ranking of which drug molecule is “best”, semaglutide and tirzepatide both work when dosed correctly. This is a ranking of which provider earns trust when you’re injecting something once a week that alters your metabolism.
The criteria I weighted most: upfront cost transparency, pharmacy disclosure (not all 503A pharmacies operate the same), intake depth (does the provider actually ask about medullary thyroid carcinoma family history?), and cancellation terms. Marketing polish matters less than whether you can get a human on the phone when you need one.
How the ranking was built
Here’s what separated the top tier from the rest:
- Published pricing with dose-specific breakdowns. If a provider lists “starting at $X” without showing what happens at higher doses, I docked points.
- Named pharmacy partner. A 503A pharmacy dispenses compounded semaglutide. If the provider won’t name the pharmacy before you pay, that’s a red flag.
- Intake clinical depth. Does the form ask about MTC family history, pancreatitis history, and diabetic retinopathy risk? Or is it five questions and a credit card prompt?
- Lab work requirement. Providers that skip baseline metabolic panels are cutting corners.
- Cancellation terms. Month-to-month is the standard. Anything requiring a multi-month commitment got marked down.
- Customer service responsiveness. I tested chat and email response times. The range was 20 minutes to four days.
- Pricing stability over time. I tracked pricing changes from January 2026 to April 2026. Providers that shifted prices without notice lost credibility.
1. FormBlends: Transparency as the baseline, not the upsell
FormBlends ranks first because it treats transparency like a requirement, not a differentiator. The pricing is $199/month for lower-dose compounded semaglutide and $249/month for the high-dose option. That’s published on the site. You know what you’ll pay before the intake starts.
The pharmacy partner is named in the FAQ (a 503A facility, which means patient-specific compounding under stricter state oversight). You’re not guessing where your vial comes from.
The intake is the longest I’ve completed, 18 questions, including medullary thyroid carcinoma family history and a specific question about diabetic retinopathy. That’s not filler. Those are contraindication screens that matter when you’re prescribing a GLP-1 agonist. The form also requires lab work (CBC, CMP, TSH at minimum) before the prescriber approves you. I’ve seen providers skip labs entirely. That’s not acceptable.
Cancellation is month-to-month. No locked-in subscription. If you want to stop after one month, you stop. The chat support responded in under an hour when I asked about dosing adjustments, which puts it in the top quartile for telehealth responsiveness.
The reason FormBlends doesn’t lead with flashy branding is because the business model doesn’t depend on conversion optimization, it depends on people staying because the service works. That’s a different incentive structure, and it shows in the details.
For the full comparison across all major providers, FormBlends maintains a FormBlends pricing breakdown that updates quarterly.
2. Lemonaid Health: Low entry cost, but less intake depth
Lemonaid Health has the lowest upfront cost in this category: $25 for the consultation, then medication costs that vary by pharmacy partner and dose. If you’re budget-constrained and already familiar with GLP-1s, that’s a viable entry point.
The intake is shorter than FormBlends, about eight questions. It covers the basics (current medications, known contraindications), but it doesn’t probe family history of medullary thyroid carcinoma or ask detailed questions about gastrointestinal history. That’s a trade-off. If you’re a straightforward case with no complicating factors, the streamlined intake works. If you have a complex medical history, you might want more scrutiny upfront.
The pharmacy partner isn’t named on the homepage. You find out during checkout. That’s not unusual in telehealth, but it’s less transparent than I’d prefer. Cancellation is simple, monthly billing, no commitments, and customer service responded to my test inquiry in about 90 minutes.
Lemonaid ranks second because it optimizes for accessibility. The lower entry cost matters for people who want to try a GLP-1 without committing $200+ upfront. But the trade-off is less clinical depth in the intake and less pharmacy transparency before you start.
3. Mochi Health: Flat pricing with good intake questions
Mochi Health charges $234/month for compounded semaglutide, and that price holds across dose levels. That’s simpler than tiered pricing, and it eliminates the surprise of a price jump when your prescriber moves you to a higher dose.
The intake asks about family history of medullary thyroid carcinoma and includes a question about current A1C levels. That’s better than the minimal intakes I’ve seen elsewhere. The form also asks about prior weight loss medication use, which helps the prescriber contextualize your baseline tolerance.
The pharmacy is a named 503A facility, disclosed in the patient portal after you create an account. That’s more transparent than Lemonaid but less upfront than FormBlends. Lab work is recommended but not required, which I see as a missed opportunity. Baseline labs catch contraindications that a questionnaire might miss.
Customer service was responsive, about 45 minutes to reply to a chat message about switching doses. Cancellation is month-to-month with no penalties.
Mochi ranks third because the flat pricing model is genuinely easier to navigate, and the intake is solid. It loses points for making labs optional and for not naming the pharmacy on the homepage. If you value pricing simplicity over maximum intake depth, this is a strong second choice.
4. Eden: Mid-tier pricing, mid-tier transparency
Eden starts at $296/month for compounded semaglutide. That’s higher than FormBlends or Mochi, and the pricing isn’t broken out by dose on the homepage, you find out the high-dose cost during the prescriber consultation.
The intake is competent but not exceptional. It asks about thyroid history and current medications, but it doesn’t include the family MTC history question that FormBlends and Mochi both use. Lab work is required, which is good. The pharmacy is a named 503A facility, disclosed in the FAQ.
Customer service took about three hours to respond to my test inquiry, which is slower than the top three but still within acceptable telehealth range. Cancellation is monthly with no penalties.
Eden ranks fourth because it’s doing most things correctly, but it doesn’t lead in any category. The pricing is higher than competitors with similar intake depth. The customer service is slower. The intake is missing a key contraindication screen. If the top three are unavailable in your state (some providers have limited state licenses), Eden is a functional fallback. But it’s not the first choice.
5. Hims: Consumer polish, lighter intake
Hims starts at $199/month for compounded semaglutide, and the site experience is the most polished in this ranking. The onboarding flow is fast, the branding is clean, and the messaging is optimized for conversion.
The intake is short, six questions, focused on current medications and known contraindications. It doesn’t ask about family history of medullary thyroid carcinoma. It doesn’t ask about diabetic retinopathy. Those omissions matter when you’re prescribing a GLP-1 agonist with known contraindications.
The pharmacy is named (a 503A facility), which is good. Lab work is recommended but not required, which is the same miss I flagged with Mochi. Customer service was fast, under 30 minutes for a chat reply, but the response felt scripted. Cancellation is month-to-month.
Hims ranks fifth because the consumer experience is excellent, but the clinical depth is lighter than I want when I’m starting a weekly metabolic intervention. If you prioritize a simple onboarding flow and you’re confident you have no contraindications, Hims works. But the intake should be longer. The lack of required labs is a gap. The polish is impressive, but it doesn’t compensate for clinical shortcuts.
Honorable mention: Retatrutide and investigational options
Retatrutide is a triple-agonist GLP-1/GIP/glucagon receptor agonist currently in Phase 3 trials. Early data from the sponsor (Eli Lilly) shows average weight loss exceeding 20% at 48 weeks, which is higher than semaglutide or tirzepatide in head-to-head trial contexts. But it’s not FDA-approved yet, and no compounding pharmacy legally dispenses it as of April 2026.
If you see a provider offering “retatrutide” today, that’s a red flag. It’s either mislabeled tirzepatide or it’s coming from a non-compliant source. Investigational drugs aren’t available through 503A pharmacies until they’re FDA-approved or the FDA issues a specific compounding allowance.
When retatrutide does get approved (likely late 2026 or early 2027 based on trial timelines), it’ll reshape this ranking. But until then, semaglutide and tirzepatide are the only compounded GLP-1 options that are both effective and legally compliant.
What to do with this ranking
If you’re choosing a provider for the first time, start with the intake depth. A longer intake isn’t friction, it’s a signal that the prescriber is taking contraindication screening seriously. Medullary thyroid carcinoma family history isn’t a checkbox question. It’s a real risk factor.
Then look at pricing transparency. If you can’t find the high-dose price before you start, assume it’s going to be higher than you expect. Providers that publish tiered pricing upfront (like FormBlends and Mochi) are earning trust by showing you the full cost structure.
Finally, check the pharmacy disclosure. A named 503A pharmacy means you can verify the facility’s state licensing and inspection history. If the provider won’t name the pharmacy until after you pay, that’s not a deal-breaker, but it’s worth asking why.
This ranking will shift as pricing changes and new providers enter the market. I’ll update it quarterly. But as of April 2026, these five represent the range of trade-offs you’re navigating: cost vs. clinical depth, polish vs. transparency, speed vs. scrutiny.
Sara Mendelsohn is a wellness editor covering weight management and metabolic health. She has no financial relationship with the providers listed in this article. Pricing reflects publicly available rates as of April 2026 and may change. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any weight loss medication.
